Skip to content
Jump to main navigation and login
Nav view search
You are here:
Latest Bing Center News
Latest News in the Treatment of WM - TELECONFERENCE 3/19/2020
CancerCare, in association with the IWMF, is holding a Teleconference titled – The Latest News in the Treatment of Waldenstrom’s Macroglobulinemia on Thursday, March 19th from 1:10-2:30 pm Eastern Time (ET). Presenting will be Steven Treon, MD, Ph.D, Christian Buske, MD, Carolyn Messner, DSW, OSW-C, FAPOS, FAOSW, and Carl Harrington (IWMF).
25th Annual IWMF Educational Forum
25th Annual IWMF Educational ForumJune 5-7, 2020Renton, WA"2020 Vision: A World Without WM"
Steven Treon, MD, PhD to serve as advisor to IWMF Board
Dr. Steven Treon, MD, PhD, (Dana-Farber Cancer Institute) has agreed to advise the IWMF Board of Trustees. Dr. Treon joins Dr. Ansell of the Mayo Clinic in providing the critical perspective of world-renowned clinicians/researchers to the IWMF Board. Dr. Treon and Dr. Ansell also will jointly co-chair the IWMF Scientific Advisory Committee.
Florida Blood Cancer Conference 2020 (LLS)
Dr. Steven Treon will be lecturing at the upcoming Blood Cancer Conference (BCC), one of many programs developed by The Leukemia & Lymphoma Society (LLS) to meet the needs of patients, survivors, families and oncology professionals, the people who deal with blood cancer every day and the people who care for them. BCC attendees receive the most current information and access to local resources to help navigate and make informed decisions about their treatment and survivorship.
ASH 2019 - Bing Center Presentations
The ASH 2019 conference was held in Orlando, FL from December 7-10, 2019. Researchers from the Bing Center contributed an oral presentation (Guang Yang), and three posters (Jorge Castill, and Xia Liu).
IWMF Adds Three Members to Scientific Advisory Committee
The IWMF is proud to welcome three new members to its Scientific Advisory Committee (SAC) chaired by Dr. Stephen Ansell of the Mayo Clinic and Dr. Steven Treon of the Dana-Farber Cancer Institute. The new members, Dr. Zachary Hunter from Dana-Farber, Boston, USA, Dr. Christian Buske from Ulm, Germany, and Dr. Monique Minnema of The Netherlands, were invited to participate because of their expertise in specific research areas identified by the IWMF-LLS Strategic Research Roadmap for WM.
Dr. Edward Laane - Running for WM! (Part-2)
On November3, 2019, Dr. Edward Laane ran the Osaka Yodo River Half Marathon, to raise money for Waldenstrom's research. His pure running time was 2.26.07 with his official time listed at 2.31.0. As Dr. Laane recalls, "The run was difficult. It was sunny, and a little bit hot. The first part, 6.5 miles was a little easier. My time was approximately 1h 10 min, but the second part was very difficult. But I was thinking about the patients who have gone through so much treatment and this gave me more strength to finish.
New Approaches to treating Waldenstrom's Macroglobulinemia
At the 2019 Lymphoma & Myeloma Congress, Steven Treon, MD, PhD, FACP, FRCP, Harvard University, Dana-Farber Cancer Institute, Bing Center for Waldenström Macroglobulinemia, Boston, Massachusetts, provided an update on the latest research in the treatment of Waldenström Macroglobulinemia.
Dr. Edward Laane - Running for WM!
Dr. Edward Laane is running in the Osaka Yodo River Citizens Marathon to raise money for Waldenstrom's research!
IMW-17 Young Investigator Awards
Congratulations to the following Bing Center researchers for their Young Investigator Awards at the 17th International Workshop on Multiple Myeloma!
The clinical trials listed below have been completed and are closed to enrollment:
Rituximab plus Fludarabine for patients with WM
Phase-2: Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia
Phase II Study of VELCADE (PS-341) in WM
Phase II Study of Thalidomide and Rituximab for patients with WM
Phase II Study of Simvastatin in WM
Phase II Study of Perifosine in Patients with Relapsed/Refractory WM
Phase II Study of Imatinib Mesylate (Gleevec) in Relapsed or Refractory WM
Phase II Study of Combination Therapy with bortezomib and rituximab in patients with relapsed/refractory Waldenstrom’s macroglobulinemia.
Phase II Study of CC-5013 (Lenalidomide , Revlimid(tm)) and rituximab in Waldenstrom's macroglobulinemia
Phase II Clinical Trial of Sildenafil Citrate in WM
Phase II Clinical Trial of RAD001 in relapsed/refractory lymphoma
Phase II Clinical Trial of combination therapy with bortezomib, dexamethasone, and rituximab in patients with WM
Extended Rituximab for patients with WM
Campath-1H for patients with relapsed and refractory WM
An Open Label, Multicenter Phase-2 Study of Single-Agent Enzastaurin HCl in Previously Treaed Waldenstrom's Macroglobulinemia or Multiple Myeloma